Shares of The Advisory Board Co. (NASDAQ:ABCO) fell 3.4% during mid-day trading on Tuesday . The stock traded as low as $37.32 and last traded at $37.67, with a volume of 101,914 shares trading hands. The stock had previously closed at $39.00.

Several brokerages recently issued reports on ABCO. Canaccord Genuity reaffirmed a “buy” rating on shares of The Advisory Board in a research note on Sunday, May 29th. KeyCorp reaffirmed a “hold” rating on shares of The Advisory Board in a research note on Sunday, May 22nd. FBR & Co reaffirmed a “hold” rating on shares of The Advisory Board in a research note on Sunday, May 8th. Robert W. Baird reaffirmed a “hold” rating on shares of The Advisory Board in a research note on Sunday, May 8th. Finally, Raymond James Financial Inc. cut shares of The Advisory Board from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $40.80.

The firm’s market cap is $1.56 billion. The firm has a 50 day moving average of $35.37 and a 200 day moving average of $35.27.

The Advisory Board (NASDAQ:ABCO) last posted its earnings results on Thursday, May 5th. The company reported $0.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.39 by $0.07. The business had revenue of $200.70 million for the quarter, compared to analysts’ expectations of $201.74 million. The business’s revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.30 earnings per share. On average, analysts predict that The Advisory Board Co. will post $1.71 earnings per share for the current year.

In other news, Director Kelt Kindick purchased 5,000 shares of the stock in a transaction dated Tuesday, May 31st. The stock was acquired at an average cost of $32.81 per share, for a total transaction of $164,050.00. Following the completion of the acquisition, the director now directly owns 22,662 shares in the company, valued at approximately $743,540.22. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Several large investors recently added to or reduced their stakes in ABCO. GAM Holding AG boosted its stake in The Advisory Board by 137.2% in the fourth quarter. GAM Holding AG now owns 47,910 shares of the company’s stock valued at $2,377,000 after buying an additional 27,710 shares in the last quarter. Rhumbline Advisers boosted its stake in The Advisory Board by 6.5% in the fourth quarter. Rhumbline Advisers now owns 49,967 shares of the company’s stock valued at $2,479,000 after buying an additional 3,045 shares in the last quarter. New York State Common Retirement Fund boosted its stake in The Advisory Board by 51.0% in the fourth quarter. New York State Common Retirement Fund now owns 94,606 shares of the company’s stock valued at $4,693,000 after buying an additional 31,963 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in The Advisory Board by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 96,676 shares of the company’s stock valued at $4,796,000 after buying an additional 577 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its stake in The Advisory Board by 17.1% in the fourth quarter. Nationwide Fund Advisors now owns 109,115 shares of the company’s stock valued at $5,413,000 after buying an additional 15,904 shares in the last quarter.

The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.